Regenerative Medicine and Stem Cells Technologies

New research in rats suggests the possibility of bioengineering artificial ovaries in the lab to provide a safer, more natural hormone replacement therapy for women

GenSight Biologics announced Jan. 10 that the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has given the company approval to initiate its PIONEER Phase I/II study of GS030 for patients with retinitis pigmentosa (RP).

In a new study, published in Cell Reports, researchers from Queen Mary University of London used cells derived from urine to take the first step in generating an artificial adrenal gland, which could help develop future treatments for adrenal gland disorders.

Researchers in the UK and the US have taken human eggs in their most early stage and developed them to maturity in a lab for the first time.

When a soldier sustains a traumatic eye injury on the battlefield, any delay in treatment may lead to permanent vision loss. With medical facilities potentially far away and no existing tools to prevent deterioration, medics are in a high-stakes race against the clock.

Adipose tissue is a source of adipose-derived stromal/stem cells for tissue engineering and reconstruction and a tissue source for fat grafts. Although liposuction is a simple procedure for the harvest of adipose tissue, the repetition of this surgical intervention can cause adverse effects to the patient and can be a limiting factor for immediate use.

The treatment of large bone defects in the upper or lower extremities (for instance, as the result of acute trauma, infection or bone cancer) remains a challenge in the field of trauma surgery. Bone defects of this kind do not heal on their own and, in particularly severe cases, will result in amputation of the affected limb.

University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the surface of leukemia cells in patients who have received stem cell transplants. Researchers plan to use their findings to develop immune-based therapies that target these antigens in leukemia patients.

Increased life expectancy, due to the rise in life quality and the decline in mortality rates, is leading to a society in which the population aged 60 and over is growing more rapidly than the entire population.

A potential new cell-free treatment for severe burns and chronic wounds that was developed by scientists at Wake Forest Institute for Regenerative Medicine (WFIRM) has been exclusively licensed to XCell Biologix, a private company that aims to make the therapy available to patients worldwide.